Charles River Laboratories International, Inc. (NYSE:CRL) Shares Sold by Rhenman & Partners Asset Management AB

Rhenman & Partners Asset Management AB reduced its holdings in Charles River Laboratories International, Inc. (NYSE:CRLFree Report) by 13.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 38,000 shares of the medical research company’s stock after selling 6,000 shares during the period. Rhenman & Partners Asset Management AB’s holdings in Charles River Laboratories International were worth $8,983,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Meritage Group LP purchased a new stake in Charles River Laboratories International in the 3rd quarter worth $173,174,000. Norges Bank acquired a new position in shares of Charles River Laboratories International during the 4th quarter worth about $101,319,000. Montrusco Bolton Investments Inc. lifted its stake in Charles River Laboratories International by 35.8% in the 3rd quarter. Montrusco Bolton Investments Inc. now owns 855,387 shares of the medical research company’s stock valued at $164,058,000 after buying an additional 225,562 shares in the last quarter. KBC Group NV lifted its stake in Charles River Laboratories International by 5,003.9% in the 4th quarter. KBC Group NV now owns 215,639 shares of the medical research company’s stock valued at $50,977,000 after buying an additional 211,414 shares in the last quarter. Finally, Armistice Capital LLC purchased a new stake in Charles River Laboratories International during the 3rd quarter worth approximately $30,573,000. 98.91% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts have recently weighed in on CRL shares. Guggenheim downgraded Charles River Laboratories International from a “buy” rating to a “neutral” rating in a research report on Thursday, February 15th. TD Cowen reduced their price objective on Charles River Laboratories International from $260.00 to $228.00 and set a “hold” rating on the stock in a research report on Monday, May 13th. JPMorgan Chase & Co. raised their price objective on shares of Charles River Laboratories International from $270.00 to $280.00 and gave the stock an “overweight” rating in a research report on Thursday, February 15th. Robert W. Baird decreased their target price on shares of Charles River Laboratories International from $282.00 to $270.00 and set an “outperform” rating on the stock in a report on Friday, May 10th. Finally, StockNews.com lowered shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Saturday, May 25th. Five analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $255.27.

View Our Latest Report on CRL

Charles River Laboratories International Trading Up 1.1 %

Shares of Charles River Laboratories International stock traded up $2.30 on Tuesday, reaching $210.23. The company had a trading volume of 601,715 shares, compared to its average volume of 554,148. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.37 and a current ratio of 1.75. The firm has a market cap of $10.83 billion, a PE ratio of 24.46, a PEG ratio of 1.97 and a beta of 1.40. The firm’s 50 day moving average price is $235.38 and its two-hundred day moving average price is $231.17. Charles River Laboratories International, Inc. has a 52-week low of $161.65 and a 52-week high of $275.00.

Charles River Laboratories International (NYSE:CRLGet Free Report) last released its quarterly earnings results on Thursday, May 9th. The medical research company reported $2.27 EPS for the quarter, beating the consensus estimate of $2.05 by $0.22. Charles River Laboratories International had a net margin of 10.81% and a return on equity of 15.16%. The firm had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $997.24 million. Sell-side analysts predict that Charles River Laboratories International, Inc. will post 11 earnings per share for the current fiscal year.

Insider Activity at Charles River Laboratories International

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 1,304 shares of the company’s stock in a transaction on Friday, May 10th. The shares were sold at an average price of $226.97, for a total transaction of $295,968.88. Following the completion of the transaction, the executive vice president now owns 23,276 shares in the company, valued at approximately $5,282,953.72. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 1.30% of the stock is owned by insiders.

Charles River Laboratories International Profile

(Free Report)

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).

Featured Stories

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRLFree Report).

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.